While many headline-grabbing biologics and advanced therapeutics like cell and gene therapies are approved as injectables, ...
The pharmaceutical supply chain and device development have become intricately linked. Harmonizing formulation development ...
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is advancing the development of a next-generation "Melt in Your ...
The Nutraceutical Excipients Market was valued at USD 4.5 billion in 2024, reflecting strong expansion driven by the rising consumption ...
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC37 oral tablets, its first oral GLP-1R/GIPR/GCGR[1] triple peptide agonist, as a clinical development candidate.
Drug discovery is a high-risk, high-cost endeavor, with over 90% of candidates failing in clinical development. A significant proportion of these failures stem from unresolved biopharmaceutic ...
Zydus Life gets tentative FDA nod for empagliflozin and linagliptin tablets to treat type 2 diabetes
The combination of empagliflozin and linagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. Shares of Zydus Lifesciences Ltd ended at ...
Detailed price information for Rapport Therapeutics Inc (RAPP-Q) from The Globe and Mail including charting and trades.
PwdRx novel drug delivery platform demonstrated superior bioavailability and accelerated absorption of cannabinoids in preclinical ...
Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026More than 21 ...
Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.
Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback